Federal Register / Vol. 69, No. 27 / Tuesday, February 10, 2004 / Notices 6313

Rucker, J.D., at the Office of Technology 

Transfer, National Institutes of Health, 

6011 Executive Boulevard, Suite 325, 

Rockville, Maryland 20852–3804; 

telephone: 301–435–4478; fax: 301–

402–0220; email: 

ruckersu@mail.nih.gov.

Met Proto-Oncogene and a Method for 

Predicting Breast Cancer Progression 

Ilan Tsarfaty, James H. Resau, Iafa 

Keydar, Donna Faletto, George F. Vande 

Woude (NCI); U.S. Patent 6,673,559 

issued 06 Jan 2004 (DHHS Reference 

No. E–046–1991/3–US–01). 

The invention described and claimed 

in this patent is generally applicable to 

assessing the prognosis of cancer. In 

particular, the invention is useful in 

assessing the whether or not breast 

cancer is likely undergo metastasis. The 

met proto-oncogene is located on the 

long arm of chromosome 7 at 7q31. Its 

activity has been linked to the invasive/

metastatic phenotype of several cancers 

in addition to breast cancer, e.g.

prostate, stomach. 

According to this invention the 

likelihood of metastasis of breast cancer 

is assessed by measuring the amount of 

(a) protein produced by the met protooncogene, (b) levels of the met protooncogene itself, or (c) levels of mRNA 

produced by the met proto-oncogene in 

breast tumor tissue and comparing it 

with the amount present in normal 

ductal tissue of the breast. The 

methodology of this invention may be 

carried out, for example, using 

antibody-based assays (ELISA or 

Western Blot), PCR, or Northern Blots. 

This work has been published at 

Tsarfaty, et al., Science 257(5074): 

1258–61 (Aug 28 1992), Tsarfaty, et al., 

Anal Quant Cytol Histol 21(5): 397–408 

(Oct 1999) and Hay, et al., J Cell 

Biochem Suppl 39(): 184–93 (2002). 

Foreign patent protection is not 

available for any of these inventions. 

Method of Targeting DNA 

Rafael D. Camerini-Otero, Margaret 

McIntosh, Carol S. Camerini-Otero and 

Lance J. Ferrin (NIDDK); U.S. Patent 

5,460,941 issued 24 Oct 1995 (DHHS 

Reference No. E–006–1991/1–US–02). 

Cloning of the RecA Gene From 

Thermus Acquatics YT–1

Rafael D. Camerini-Otero and Evelina 

Angov (NIDDK); U.S. Patent 5,510,473 

issued 23 Apr 1996 (DHHS Reference 

No. E–196–1993/0–US–01). 

Rec-A Assisted Cloning of DNA 

Lance J. Ferrin, Rafael D. CameriniOtero (NIDDK); U.S. Patent 5,707,811 

issued 13 Jan 1998 (DHHS Reference 

No. E–166–1995/0–US–02). 

Promotion of Homologous DNA Pairing 

by RecA-derived Peptides 

Oleg Voloshin, Lijiang Wang, Rafael 

D. Camerini-Otero (NIDDK); U.S. Patent 

5,731,411 issued 24 Mar 1998 (DHHS 

Reference No. E–139–1995/0–US–01). 

These inventions are available for 

license separately or together. Foreign 

patent protection is not available for any 

of these inventions. 

The inventions described in these 

patents are generally applicable to the 

process of homologous DNA 

recombination. The inventions may be 

used in conjunction with each other, to 

efficiently carry out the process of 

homologous recombination, or they may 

be used separately. 

The inventions may be exploited 

generally in processes associated with 

therapeutic purposes such as gene 

inactivation, correction of gene 

mutations and the control of gene 

expression. For example, these 

inventions may be used to inhibit the 

transcription of a DNA sequence such as 

that encoding an oncogene or a virus. In 

addition, these inventions may be 

exploited in research applications such 

as sequence-specific mapping, cloning, 

and manipulation of complex genomes 

including the generation of transgenic 

animals. 

Specific examples of the use of these 

inventions include (a) protecting a DNA 

sequence from modification by an 

enzyme such as methylase or cleavage 

by a restriction enzyme, (b) effecting 

site-specific cleavage by introducing a 

chemical cleavage moiety to the 

oligonucleotide, (c) cloning a genomic 

DNA fragment containing a 

predetermined sequence, (d) identifying 

a genetic mutation, e.g., point 

mutations, insertions and deletions, and 

(e) increasing the stringency thereby 

improving the specificity of DNA-DNA, 

DNA-RNA or RNA-RNA interactions at 

high temperatures. 

This work has been published at 

Hsieh et al., Genes & Dev. 4(11): 1951–

63 (Nov 1990); Angov et al., J. Bacteriol.

176(5): 1405–12 (Mar 1994); Voloshin et 

al., Science 272(5263): 868–72 (May 10, 

1996); and Ferrin LJ, Genet. Eng. (NY)

17: 21–30 (1995).

Dated: February 2, 2004. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health.

[FR Doc. 04–2765 Filed 2–9–04; 8:45 am] 

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Diabetes and 

Digestive and Kidney Diseases; Notice 

of Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meetings will be open to the 

public as indicated below, with 

attendance limited to space available. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy.

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Initial Review Group, Diabetes, 

Endocrinology and Metabolic Diseases B 

Subcommittee. 

Date: March 22–24, 2004. 

Open: March 22, 2004, 7 p.m. to 7:30 p.m. 

Agenda: To review procedures and discuss 

policies. 

Place: Double Tree Rockville, 1750 

Rockville Pike, Rockville, MD 20852. 

Closed: March 22, 2004, 7:30 p.m. to 10 

p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Double Tree Rockville, 1750 

Rockville Pike, Rockville, MD 20852. 

Closed: March 23, 2004, 8 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Double Tree Rockville, 1750 

Rockville Pike, Rockville, MD 20852. 

Closed: March 24, 2004, 8:00 a.m. to 3 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Double Tree Rockville, 1750 

Rockville Pike, Rockville, MD 20852. 

Contact Person: John F. Connaughton, PhD, 

Scientific Review Administrator, Review 

Branch, DEA, NIDDK, National Institutes of 

Health, Room 757, 6707 Democracy 

Boulevard, Bethesda, MD 20892. (301) 594–

7797; connaughtonj@extra.niddk.nih.gov.

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Initial Review Group, Digestive Diseases and 

Nutrition C Subcommittee. 

6314 Federal Register / Vol. 69, No. 27 / Tuesday, February 10, 2004 / Notices 

Date: March 22–24, 2004. 

Open: March 22, 2004, 7 p.m. to 7:30 p.m. 

Agenda: To review procedures and discuss 

policies. 

Place: Double Tree Rockville, 1750 

Rockville Pike, Rockville, MD 20852. 

Closed: March 22, 2004, 7:30 p.m. to 10 

p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Double Tree Rockville, 1750 

Rockville Pike, Rockville, MD 20852. 

Closed: March 23, 2004, 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Double Tree Rockville, 1750 

Rockville Pike, Rockville, MD 20852. 

Closed: March 24, 2004, 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Double Tree Rockville, 1750 

Rockville Pike, Rockville, MD 20852.

Contact Person: Carolyn Miles, PhD, 

Scientific Review Administrator, Review 

Branch, DEA, NIDDK, National Institutes of 

Health, Room 755, 6707 Democracy 

Boulevard, Bethesda, MD 20892. (301) 594–

7791; milesc@extra.niddk.nih.gov.

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Initial Review Group, Kidney, Urologic and 

Hematologic Diseases D Subcommittee. 

Date: March 23–24, 2004. 

Open: March 23, 2004, 8 a.m.to 8:30 a.m. 

Agenda: To review procedures and discuss 

policies. 

Place: Double Tree Rockville, 1750 

Rockville Pike, Rockville, MD 20852.

Closed: March 23, 2004, 8:30 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Double Tree Rockville, 1750 

Rockville Pike, Rockville, MD 20852.

Closed: March 24, 2004, 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Double Tree Rockville, 1750 

Rockville Pike, Rockville, MD 20852. 

Contact Person: Neal A. Musto, PhD, 

Scientific Review Administrator, Review 

Branch, DEA NIDDK, National Institutes of 

Health, Room 751, 6707 Democracy 

Boulevard, Bethesda, MD 20892. (301) 594–

7798; muston@extra.niddk.nih.gov.

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.847, Diabetes, 

Endocrinology and Metabolic Research; 

93.848, Digestive Diseases and Nutrition 

Research; 93.849, Kidney Diseases, Urology 

and Hematology Research, National Institutes 

of Health, HHS.) 

Dated: February 4, 2004. 

LaVerne Y. Stringfield, 

Director, Office of Federal Advisory 

Committee Policy.

[FR Doc. 04–2766 Filed 2–9–04; 8:45 am] 

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institutes of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy.

Name of Committee: Microbiology, 

Infectious Diseases and AIDS Initial Review 

Group, Microbiology and Infectious Diseases 

Research Committee. 

Date: February 25–27, 2004. 

Time: 8 a.m. to 3 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda Marriott, 5151 Pooks Hill 

Road, Bethesda, MD 20814. 

Contact Person: Gary S. Madonna, PhD, 

Scientific Review Administrator, Scientific 

Review Program, Division of Extramural 

Activities, NIAID, NIH, Room 2149, 6700–B 

Rockledge Drive, MSC 7616, Bethesda, MD 

20892–7616, Bethesda, MD 20892–7616. 

301–496–3528; gm12w@nih.gov.

This notice is being published less 

than 15 days prior to the meeting due 

to the timing limitations imposed by the 

review and funding cycle.

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS.)

Dated: February 4, 2004. 

LaVerne Y. Stringfield, 

Director, Office of Federal Advisory 

Committee Policy.

[FR Doc. 04–2767 Filed 2–9–04; 8:45 am] 

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552(b)(c)(6), title 5 

U.S.C., as amended. The grant 

applications and the discussions could 

disclose confidential trade secrets or 

commercial property such as patentable 

material, and personal information 

concerning individuals associated with 

the grant applications, the disclosure of 

which would constitute a clearly 

unwarranted invasion of personal 

privacy.

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel, Comprehensive 

International Program of Research on AIDS 

(CIPRA). 

Date: February 26, 2004. 

Time: 1 p.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health/NIAID, 

6700B Rockledge Drive, 3125, Bethesda, MD 

20895 (Telephone Conference Call). 

Contact Person: Eugene R. Baizman, PhD, 

Scientific Review Administrator, NIH/NIAID/

DEA, Scientific Review Program, Room 3125, 

6700B Rockledge Drive, Bethesda, MD 

20892–7616, 301 496–2550, eb237e@nih.gov.

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS)

Dated: February 4, 2004. 

LaVerne Y. Stringfield, 

Director, Office of Federal Advisory 

Committee Policy.

[FR Doc. 04–2768 Filed 2–9–04; 8:45 am] 

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which